A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia

NCT02733042 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

106

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma
Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

DRUG: Durvalumab
DRUG: Lenalidomide
DRUG: Rituximab
DRUG: Ibrutinib
DRUG: Bendamustine

Sponsor

Celgene